Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 01, 2024
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Journal: The New England journal of medicine
Published: March 20, 2024
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Journal: Therapeutic advances in medical oncology
Published: March 08, 2023
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.
Journal: British journal of clinical pharmacology
Published: December 13, 2021
Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.
Journal: PloS one
Published: September 10, 2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 24, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 15, 2020
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Journal: Anti-cancer drugs
Published: March 16, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: February 21, 2019
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy.
Journal: International journal of breast cancer
Published: May 02, 2017
Last Updated: 09/26/2026